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Available online 23 May 2017Background: Carﬁlzomib (CFZ) is a new proteasome inhibitor used for the treatment of multiple myeloma. Be-
sides heart failure, angina and myocardial ischemia occurred following administration of CFZ, which is not con-
traindicated in patients with recent myocardial infarction/unstable angina excluded from the safety trials.
Aim of Study: To test the effects of CFZ (10−9 to 10−7 mol/L) on vascular tone and reactivity in the isolated rabbit
heart and aorta.
Methods and Results: CFZ administered by bolus injection to the isolated heart increased coronary perfusion pres-
sure (CPP) at all tested concentrations and mildly raised left ventricular pressure and heart rate, only at the
highest concentration. Addition of CFZ directly into the organ bath increased the basal tone of isolated aortic
strips with contraction plateau reached after 10 min. This spasmogenic effect doubled following ablation of the
endothelium. Pretreatmentwith CFZ ampliﬁed the vasospastic action exerted byKCl, noradrenaline (NA) and an-
giotensin II (A) on aortic strips, and impaired vasodilation following administration of nitroglycerin (NTG) and
nifedipine (NFP) on the contraction plateau induced by KCl, NA and A. Aortic strips pretreatedwith CFZ exhibited
impaired relaxation, as compared to untreated strips, following administration of acetylcholine (Ach), an endo-
thelium-dependent vasodilating agent, on the plateau of NA contraction (p b 0.05).
Conclusions: CFZ increased CPP, resting vasoconstricting tone and the spasmogenic effect of different agents.
Preincubation with CFZ decreased the anti-spasmogenic activity of NTG and NFP, as well as reduced by over
50% the vasodilating effect of Ach, suggesting that CFZ can impair vasodilation via an endothelium dependent
mechanism. Further studies are warranted to establish its clinical safety in patients with known CAD and prior
history of coronary spasm.ision of C
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Vascular tone1. Introduction
Carﬁlzomib (CFZ) is a novel proteasome inhibitor given by intrave-
nous infusion for the treatment of relapsed and/or refractory Multiple
Myeloma (MM) (Neri et al., 2016). Chemically, it is a tetrapeptide
epoxyketone derived from epoxomicin, a natural product that hasardiology, Pauley Heart
chmond, VA, USA.
li).
pt.
an open access article underbeen shown to inhibit the proteasome (Meng et al., 1999). CFZ exerts
a potent and irreversible inhibition of the proteasomal chymotrypsin-
like activity, by binding selectively the β5 subunit of the 20S proteolytic
core particle, while it only has minimal afﬁnity for the β1 and β2 sub-
units (at doses up to 100 nM) (Demo et al., 2007). The U.S. Food and
Drug Administration (FDA) approved CFZ on 20 July 2012 for use in pa-
tients with MM, who have received at least two prior therapies [includ-
ing treatment with bortezomib (BTZ) and an immunomodulatory
agent] and who exhibited disease progression within 60 days of com-
pletion of the last therapy. More recently, CFZ has also been approved
for combined use with lenalidomide and dexamethasone for thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[Prescribing Information], 2015).
Proteasomes are protein complexes located in the nucleus and the
cytoplasm of all eukaryotic cells. The main function of the proteasome
is to degrade unneeded or damaged proteins by proteolysis
(Dahlmann, 2016). Proteins are tagged for degradationwith several res-
idues of a small protein called ubiquitin, with ﬁnal formation of a
polyubiquitin chain, which is bound by the proteasome (Yao and
Cohen, 2002). The ubiquitin-proteasome pathway (UPP) inﬂuences es-
sential cellular functions including cell growth, differentiation, apopto-
sis, signal transduction, antigen processing and the inﬂammatory
response. Proteasome inhibitors have effective anti-tumor activity. Se-
lective inhibition in cancer cells of proteasome-mediated proteolysis re-
sults in a build-up of polyubiquinated proteins, which may cause cell
cycle arrest, apoptosis, and inhibition of tumor growth (Grigoreva et
al., 2015).
Chronic proteasome inhibitionwas associatedwith increased oxida-
tive stress and early occurrence of atherosclerosis in a pig model of cor-
onary artery disease (CAD) (Herrmann et al., 2007). In the same animal
model, inhibition of the proteasome resulted in functional and structur-
al alteration of the heart consistent with a hypertrophic-restrictive car-
diomyopathy phenotype (Marfella et al., 2008). Sustained proteasome
inhibition was also found to promote vascular cell senescence, thereby
contributing to plaque progression, in asymptomatic elderly and adult
patients undergoing carotid endarterectomy (Herrmann et al., 2013).
Although CFZ has a more favorable safety proﬁle than other protea-
some inhibitors, such as BTZ, mostly in regard to the lower incidence of
peripheral neuropathy, analysis of the available clinical data seems to
endorse the above experimental ﬁndings, conﬁrming that treatment
with CFZ may be associated with signiﬁcant cardiovascular
complications.
The safety proﬁle of CFZ used as a single agent for the treatment of
relapsed and/or refractory MM was analyzed in a total of 526 patients
enrolled in the four phase II clinical trials based on which the U.S. FDA
approval was granted. The most severe side effects reported include:
sudden death (within 24h from the infusion), pulmonary hypertension,
heart failure (HF) (7.2%), myocardial ischemia and infusion reactions.
Chest tightness of unknownmechanism has also been described and re-
ported (Siegel et al., 2013).
Likewise, in the phase III, randomized, multicenter studies ASPIRE
(Carﬁlzomib, Lenalidomide, and Dexamethasone versus Lenalidomide
and Dexamethasone for the Treatment of Patients with Relapsed Multi-
ple Myeloma) (Stewart et al., 2015) and ENDEAVOR (Phase 3 Study
With Carﬁlzomib and Dexamethasone Versus Bortezomib and Dexa-
methasone for Relapsed Multiple Myeloma Patients) (Dimopoulos et
al., 2015a; Dimopoulos et al., 2015b), the use of CFZ as part of combina-
tion regimens in patients with relapsed or refractory MM resulted in
signiﬁcantly higher rates of cardiac and cardiopulmonary adverse
events including dyspnea, HF, ischemic heart disease and hypertension.
The goal of our study was to investigate whether CFZ exerts in vitro
effects on vascular tone and reactivity in the isolated rabbit heart and
thoracic aortic strips. The isolated heart was used to assess the effect
of CFZ onmyocardial contractility and coronary resistances. The thorac-
ic aortic strips with andwithout endotheliumwere used to evaluate the
effects of CFZ on vascular smooth muscle tone.
2. Methods
2.1. Rabbit Heart Preparations
All animal experiments were conducted ethically and approved by
pertinent ethics committee. New Zealand albino rabbits of both sexes
weighing 2–2.5 kg were used. The animals were sacriﬁced by cervical
dislocation. The hearts were removed quickly and placed in an ice-
cold Ringer-Locke solution, oxygenated with 100% O2, and containing
in millimoles per liter: NaCl, 136.9; KCl, 2.68; MgCl, 0.99; CaCl2, 1.7;NaHPO4, 0.42; NaHCO3, 3.93; and glucose, 5.55 (pH 7.4) (Raddino et
al., 1997).
Using a previously described procedure (Broadley, 1979), after re-
moval of the pericardium and surrounding tissues, the hearts were per-
fused with Ringer-Locke solution according to the nonrecirculating
Langendorff technique. The perfusion ﬂuid was continuously gassed
with 100% O2, maintained at 37 degrees Celsius, and delivered to the
aortic inﬂow cannula at a constant rate of 22–24 ml/min using a peri-
staltic pump (Gilson, Miniplus HP2HF). The perfusion pressure was
measured by a Statham transducer connected to the sidearm of the per-
fusion cannula. Since retrograde ﬂow (coronary ﬂow) was kept con-
stant during the experiment, coronary perfusion pressure (CPP)
represented a direct measure of the coronary resistance. A ﬂuid-ﬁlled
balloon connected to a pressure transducer was inserted into the left
ventricular cavity through an opening in the left atrium, thus obtaining
an isovolumically beating preparation. The balloon was inﬂated to pro-
vide an end-diastolic pressure b 1.0 mm Hg (Ferrari et al., 1996). Both
end systolic left ventricular pressure (LVP) and CPP were recorded si-
multaneously by using a polygraph (OTE Biomedica; C6B). Except for
experiments evaluating chronotropic effects, the hearts were electrical-
ly paced to exclude LVP variations related to heart rate (HR) oscillations.
Rectangular pulses (0.5 V@ 1.0msec, up to threshold stimulation)were
applied to the preparation via two platinum electrodes, one connected
to themetal inﬂow cannula and the other implanted directly in the ven-
tricular apex. The frequency of stimulation was 10% greater than the
basal HR. The hearts were left to equilibrate for 30min prior to drug ad-
ministration. The maximal effects of the used agents were observed 5–
15 min after addition to the perfusion ﬂuid (Ferrari et al., 1996). CFZ
was administered in the perfusion buffer or infused at three different
concentrations (10−9, 10−8 and 10−7 M) by bolus injection of 1 cc
over 5 min, using a collateral arm of the perfusion cannula. The above
concentrations were chosen based on prior in vitro work showing that
carﬁlzomib doses ranging from 5 to 80 nmol/L resulted in a signiﬁcant
growth inhibition of mantle cell lymphoma (MCL) cells, harvested
from peripheral blood samples or bone marrow aspirates obtained
from patients with MCL (Zhang et al., 2013).
2.2. Aortic Preparations
After surgical isolation of the aortic segments, the media was sepa-
rated from the adventitia and spirally cut into strips, according to
Furchgott's technique (Furchgott and Zawadzki, 1980). The thoracic
aortic strips (2 cm long and 3 mm wide) were then placed in 10 ml
organ baths containing Krebs-Henseleit solution at 37 °C. Contractions
were measured by means of an isometric transducer, connected to a
pen writing recorder. An initial tension of 2 g was applied for 120 min
before the administration of drugs. The effect of three different
spasmogenic agents [potassium chloride (KCl, noradrenaline (NA),
and angiotensin II (A))] was evaluated on aortic strips either untreated
or precontracted for 60 min with CFZ. KCl (10−1 M), NA (10−6 M) and
A2 (10−5 M)were administered directly into the organ bath. In a differ-
ent set of experiments, following achievement of the plateau of contrac-
tion (usually 5–10 min after the administration) induced by CFZ,
vasodilatory agents, such as nitroglycerin (NTG) and nifedipine (NFP)
were added to the organ bath at different concentrations, ranging
from 10−9 to 10−5 M. Some aortic strips were rubbed to eliminate the
endothelial layer, whose absence was pharmacologically tested and
conﬁrmed by means of the acetylcholine test (Furchgott and
Zawadzki, 1980). Endothelium-dependent vascular reactivity was also
assessed by evaluating the antagonism induced by acetylcholine (Ach;
10−8 to 10−5 M) during NA-induced specimen contraction (10−5 M).
2.3. Data Analysis
Results were expressed asmean± SEM of 6–8 experiments. The in-
hibitory response on LVP and CPP was calculated as a percentage
Fig. 1. a) Effects on left ventricular pressure (LVP) and heart rate (HR) of carﬁlzomib administered in the perfusion buffer (concentrations: 10−9, 10−8 and 10−7 mol/L). b) Effects on
coronary perfusion pressure (CPP) of carﬁlzomib administered in the perfusion buffer (concentrations: 10−9, 10−8 and 10−7 mol/L). *p b 0.05 versus baseline.
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nary spasm was assessed as a percentage of inhibition on the plateau
of the CPP increase induced by different spasmogenic compounds. Sta-
tistical analysis was performed by analysis of variance and test of simple
main effects. Comparison between groups was performed using the
Student's t-test for unpaired data. The level of signiﬁcance was consid-
ered as p b 0.05.2.4. Drugs
All the drugs and reagents were purchased from Sigma-Aldrich (St.
Louis, MO, U.S.A.). Carﬁlzomib was solubilized in dimethyl sulfoxide
(DMSO) at 10 mmol/L.Fig. 3. a) Effects of nitroglycerin (NTG) on the coronary perfusion pressure (CPP) increase induc
and **p b 0.01 versus CPP increase induced by CFZ 10−7mol/L. b) Effects of nifedipine (NFP) on t
rabbit heart. ***p b 0.001 versus baseline; *p b 0.05 and **p b 0.01 versus CPP increase induced
Fig. 2. a) Effects on coronary perfusion pressure (CPP) of carﬁlzomib administered at three diff
using a collateral arm of the perfusion cannula. *p b 0.05, **p b 0.01 versus bolus injections of
perfusion through the aortic inﬂow cannula at a constant rate of 22–24 ml/min. b) Effects on
different concentrations (10−9, 10−8 and 10−7 mol/L) by injection of 1 cc boluses over 5 min3. Results
3.1. Isolated Heart
After the stabilization period, the isolated hearts showed a basal LVP
of 55.1±5.2mmHg and a basal CPP of 62.6±3.9mmHg. Basal HRwas
135.8± 8.5 beats/min (data not shown). Pilot experiments revealed os-
cillations in basal LVP and CPP b 5% after 120min; likewise, a spontane-
ous reduction in HR of 11.7± 1.1%was also recorded. CFZ administered
in the perfusion ﬂuid at concentrations of 10−9, 10−8 and 10−7 M did
not substantially modify LVP and HR values (p N 0.05), whereas CPP
was slightly increased from 65.2 ± 4.1 to 78.6 ± 8.3 mm Hg, but only
at the highest concentration of 10−7mol/L (p b 0.05) (Fig. 1a andb). Ad-
ministration of CFZ by bolus injection caused a signiﬁcant increase ined by carﬁlzomib (CFZ) in the isolated rabbit heart. ***p b 0.001 versus baseline; *p b 0.05
he coronary perfusion pressure (CPP) increase induced by carﬁlzomib (CFZ) in the isolated
by CFZ 10−7 mol/L.
erent concentrations (10−9, 10−8 and 10−7 mol/L) by injection of 1 cc boluses over 5 min
1 cc buffer over a time frame of 5 min. Baseline value of CPP was recorded during buffer
left ventricular pressure (LVP) and heart rate (HR) of carﬁlzomib administered at three
using a collateral arm of the perfusion cannula.
Fig. 5. Spasmogenic effects of potassiumchloride (KCl), noradrenaline (NA) and angiontensin II (A2) assessed on aortic strips either untreated or precontracted for 60minwith carﬁlzomib
(CFZ). **p b 0.01 versus baseline.
Fig. 4. Effects of carﬁlzomib (10−9–10−7 mol/L) on basal tone of isolated aortic strips in presence and absence of the endothelium. *p b 0.05, **p b 0.01 versus baseline.
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well as a mild increase in LVP and HR, which wasmore evident, though
still non-statistically signiﬁcant, at the maximum dosage tested
(10−7 M) (Fig. 2b). As shown in Fig. 3a and b, nitroglycerin (NTG) and
nifedipine (NFP) exhibited a signiﬁcant inhibitory effect on the
spasmogenic action exerted by CFZ. At a CFZ concentration of 10−5 M,
the percentage of inhibition for NTG, which peaked at 62.2%, was signif-
icantly higher than that for NTG, which peaked at 49.4% (p b 0.05).Fig. 6. Vasodilatory effect of nitroglycerin (NTG) and nifedipine (NFP) on the plateau of
contraction induced by carﬁlzomib used at a concentration of 10−7 mol/L. *p b 0.05 in
comparing the effects of NTG 10−5 M versus NFP 10−7 M.3.2. Aortic Strips
CFZ administered directly into the organ bath (10−9–10−7 M) sig-
niﬁcantly increased the basal tone of the isolated aortic strips with a
contraction plateau reached after 10 min incubation (Fig. 4, left
panel). The spasmogenic effectwas signiﬁcantly increased following ab-
lation of the endothelium, as shown in Fig. 4 (right panel). Subsequent-
ly, we tested the effects of different vasopressors, i.e. KCl (10−1 M), NA
(10−6 M) and A2 (10−5 M), on aortic strips either untreated or precon-
tracted with CFZ (10−7 mol/L) for 15 min. While no difference was
210 C. Chen-Scarabelli et al. / EBioMedicine 21 (2017) 206–212observed in the vasoconstrictive action of the three vasopressors, pre-
treatment with CFZ increased the tension exerted by each of the agents
by approximately 30%, as depicted in Fig. 5. The vasodilatory action ofFig. 7. a) Vasodilatory effects of nitroglycerin (NTG) (left panel) and nifedipine (NFP) (right pan
or absence of carﬁlzomib (CFZ). *p b 0.05 in the comparison between effects of NTG 10−5 M an
(NFP) (right panel) on the plateau of contraction induced by noradrenaline (NA; 10−6 M) in pr
NTG 10−5 M and NFP 10−7 M on the plateau of contraction induced by NA in presence of CFZ.
plateau of contraction induced by NA in absence of CFZ. c) Vasodilatory effects of nitroglycerin (
by angiotensin II (A-II; 10−5 M) in presence or absence of carﬁlzomib (CFZ). *p b 0.05 in the com
induced by A-II in presence of CFZ. ***p b 0.001 in the comparison between the effects of NTGNTGandNFPwas evaluated on the contraction plateau induced by incu-
bation with CFZ (10−7 mol/L) for 15 min. Although both NTG and NFP
signiﬁcantly curbed the spasmogenic effects of CFZ, an NTGel) on the plateau of contraction induced by potassium chloride (KCl; 10−1M) in presence
d NFP 10−7 M. b) Vasodilatory response to nitroglycerin (NTG) (left panel) and nifedipine
esence or absence of carﬁlzomib (CFZ). *p b 0.05 in the comparison between the effects of
**p b 0.01 in the comparison between the effects of NTG 10−5 M and NFP 10−7 M on the
NTG) (left panel) and nifedipine (NFP) (right panel) on the plateau of contraction induced
parison between the effects of NTG 10−5M and NFP 10−7M on the plateau of contraction
10−5 M and NFP 10−7 M on the plateau of contraction induced by A-II in absence of CFZ.
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signiﬁcant percentage of inhibition on CFZ-induced vasoconstriction, as
compared to an NFP concentration of 10−7 M (Fig. 6). Of note, neither
NTG nor NFP were able to totally reverse the vasoconstrictive effects
of CFZ. In another set of experiments, we assessed the vasodilation trig-
gered by NTG and NFP on the contraction plateau of aortic strips incu-
bated with KCl (10−1 M), NA (10−6 M) and A-II (10−5 M) with or
without pretreatment with CFZ (15 min at a concentration of
10−7 mol/L). Pretreatment with CFZ signiﬁcantly impaired the
vasodilatory response to NTG and NFP on the contraction plateau in-
duced by all vasopressors (Fig. 7a, b and c). A comparison between
the effects of NTG and NFP used at their highest doses revealed that
NTG's ability to cause vasodilation was signiﬁcantly more pro-
nounced than NFP's both in the presence and absence of CFZ. Endo-
thelium-dependent vascular reactivity was ﬁnally assessed by
evaluating the antagonism induced by Ach (10−8 to 10−5 M) during
NA-induced specimen contraction (10−5 M). As depicted in Fig. 8,
aortic strips pretreated with CFZ and contracted with NA exhibited
a blunted reactivity to Ach, a well-known endothelium-dependent
vasodilating agent (Fig. 8).4. Discussion
Although still incurable, the survival rate of MM, the second most
common hematologic malignancy (Siegel et al., 2014), has improved
mainly due to the development of new and highly effective agents,
such as immunomodulators and proteasome inhibitors (Kumar et al.,
2012). CFZ is an irreversible epoxyketone-based proteasome inhibitor,
used in the U.S. as a single or combination agent (along with
lenalidomide and dexamethasone) in the treatment of relapsed/refrac-
tory MM. The elevated response rate and improved progression-free
survival (PFS) observed in patients with relapsed or refractory MM re-
ceiving CFZ as a single (Siegel et al., 2013) or combination agent
(Stewart et al., 2015; Dimopoulos et al., 2015b), as well as its advanta-
geous beneﬁt-risk proﬁle in comparison to BTZ (Dimopoulos et al.,
2015b), another proteasome inhibitor, are associated with signiﬁcantly
higher cardiac and cardiopulmonary adverse events. In the ASPIRE trial,
for instance, compared to patients receiving lenalidomide and dexa-
methasone alone, those given CFZ in addition to lenalidomide and dexa-
methasone reported higher rates of grade 3 dyspnea (2.8% versus 1.8%),
HF (grouped term; 3.8% and 1.8%), ischemic heart disease (grouped
term; 3.3% and 2.1%), and hypertension (preferred term; 4.3% and
1.8%) (Stewart et al., 2015). Likewise, in the ENDEAVOR study, in com-
parison to the BTZ-dexamethasone group, the patients assigned to the
CFZ-dexamethasone developed increased rates of grade 3 hypertension
(8.9% vs. 2.6%), dyspnea (5.4% vs. 2.2%), and HF (4.8% vs. 1.8%)
(Dimopoulos et al., 2015b). Recent early-phase clinical trials exploringFig. 8. Vasodilatory effects of acetylcholine (Ach) on noradrenaline (NA)-induced
(10−6 M) contraction of aortic strips either naïve or precontracted with carﬁlzomib
(CFZ). *p b 0.05; **p b 0.01 and ***p b 0.001 in the comparison between the effects of
Ach in presence or absence of CFZ.the safety and efﬁcacy of different CFZ doses in patients with newly di-
agnosedMM also reported cardiac-related dose-limiting toxicity (DLT),
likely related to CFZ administration, with a reported maximum tolerat-
ed dose (MTD) of 20–36 mg/m2 (Bringhen et al., 2014; Mikhael et al.,
2015). The overall interpretation of the results from the phase I-III clin-
ical trials indicates an increased risk of cardiac-related events following
CFZ treatment, with a reported incidence of grade 3 HF ranging from 4
to 6% (Siegel et al., 2013; Stewart et al., 2015; Dimopoulos et al.,
2015a). Besides HF, whose etiology and pathophysiology are poorly un-
derstood, other common side effects (potentially related to the vasoac-
tive properties of CFZ) include myocardial ischemia, manifesting as
angina and myocardial infarction, as well as systemic and pulmonary
hypertension. Previous studies also reported the occurrence of chest
pain of unclear etiology during CFZ infusion. In line with this ﬁnding,
in some of our patients receiving CFZ infused at high-doses
(≥36 mg/m2), we observed cases of chest pain, sometimes associated
with ischemic alterations of the electrocardiogram, without release of
cardiac biomarkers in the circulation. This group underwent further car-
diac evaluation, which failed to unveil inducible myocardial ischemia
and/or signiﬁcant CAD. The current study stemmed from the attempt
to explain this inconsistency, by moving backwards from the bedside
to the bench. Our data showed for the ﬁrst time that CFZ exerts pow-
erful in vitro effects on vascular tone and reactivity. CFZ adminis-
tered by bolus injection heightened coronary resistance and its
spasmogenic action was only partly resolved by NTG and NFP. Of
note, the percentage inhibition achieved by NTG on CFZ-induced
spasm was signiﬁcantly higher than NFP (62.2% versus 49.4%). This
would suggest a more congruent role for nitrates, rather than calci-
um channel blockers, in the prevention and treatment of the clinical
conditions of exaggerated vascular tone, potentially related to CFZ
infusion. Furthermore, CFZ increased the resting vasoconstricting
tone of aortic strips, an effect which was further ampliﬁed by
ablation of the endothelium. Moreover, preincubation with CFZ am-
pliﬁed the spasmogenic effect of different vasopressors and mini-
mized the vasodilatory response to NTG and NFP on the contraction
plateau caused by several vasopressors. Once again, NTG proved to
be more efﬁcacious than NFP in limiting the combined spasm ensu-
ing from CFZ pretreatment and subsequent incubation with any of
the vasopressors used. Finally, after preincubation with CFZ, there
was a N50% reduction in the Ach-vasodilating effect. This ﬁnding, in
conjunction with the stronger antispasmogenic activity consistently
exhibited by NTG (as compared to NFP), suggests that CFZ can impair
vasodilation via an endothelium dependent mechanism. Since the
vasoactive effects of proteasome inhibitors other than CFZ were not
investigated, the ﬁndings of our study cannot be generalized and as-
sumed to be expression of a drug class effect. This represents a limi-
tation of our study.
The experimental data described above, although in need of proper
validation in the clinical setting, should be a cautionary tale in the man-
agement of MMpatients requiring CFZ. MM typically affects the elderly,
a population with greater cardiovascular risk factors and higher inci-
dence of cardiovascular disease. Hence,MMpatientswhose chemother-
apeutic regimen includes CFZ should be evaluated by a cardio-
oncologist and undergo comprehensive cardiovascular risk stratiﬁca-
tion, possibly including an ischemic work-up, prior to receiving CFZ in-
fusion. Remarkably, patients with New York Heart Association Class III–
IV HF, myocardial infarction or unstable angina, who were excluded
from the phase II studies based on which FDA approval was granted,
are also eligible to receive CFZ (KYPROLIS [Prescribing Information],
2016), despite the greater risk of developing cardiovascular complica-
tions, as a consequence of the infusion. As CFZ is not contraindicated
in this high-risk population and cardiac complications caused by CFZ
are serious, it is imperative that cardiovascular risk factors and underly-
ing cardiac conditions (such as HF, cardiac ischemia, systemic and pul-
monary hypertension) be thoroughly investigated, diagnosed and
treated, prior to proceeding with CFZ infusion.
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